Oscient Pharmaceuticals Corporation (“we”, “us”, or the “Company”) is a commercial-stage pharmaceutical company marketing Food and Drug Administration (“FDA”)-approved products in the United States. We have developed a commercial infrastructure including a national sales force calling on targeted primary care physicians, cardiologists, endocrinologists and pulmonologists in the United States. (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with a healthy diet. We license the rights to ANTARA from Ethypharm S.A. of France (“Ethypharm”) and began promoting ANTARA in late August 2006. In 2008, ANTARA generated approximately $70 million in net revenues. FACTIVE is indicated for the treatment of community-acquired pneumonia of mild to moderate severity (“CAP”) and acute bacterial exacerbations of chronic bronchitis (“AECB”). We license the rights to gemifloxacin, the active ingredient in FACTIVE tablets, from LG Life Sciences of the Republic of Korea (“LG Life Sciences”) and launched FACTIVE in the U.S. market in September 2004. In 2008, FACTIVE generated approximately $16 million in net revenues.
Company profile
Ticker
OSCI
Website
CEO
Christopher Tarquinio
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Genome Therapeutics Corp
SEC CIK
Corporate docs
IRS number
42297484
Latest filings (excl ownership)
25-NSE
Exchange delisting
28 Jul 09
8-K
Bankruptcy or Receivership
13 Jul 09
8-K
Other Events
22 Jun 09
8-K
Cost Associated with Exit or Disposal Activities
16 Jun 09
8-K
Other Events
29 May 09
8-K
Oscient Pharmaceuticals Receives NASDAQ Letter Regarding
22 May 09
8-K
Other Events
19 May 09
8-K
Other Events
15 May 09
NT 10-Q
Notice of late quarterly filing
15 May 09
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1 May 09
Latest ownership filings
No filings